Opdivo plus platinum-based chemotherapy is indicated to treat resectable non-small cell lung cancer patients. Credit: Ed Uthman / Flickr (Creative Commons).

The European Commission has granted approval to Bristol Myers Squibb for Opdivo (nivolumab) plus platinum-based chemotherapy to treat resectable non-small cell lung cancer (NSCLC) patients.

The neoadjuvant treatment is indicated for adult individuals with NSCLC with tumour cell PD-L1 expression greater than or equal to 1%, who are at increased risk of recurrence.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Opdivo with chemotherapy is the first therapy option of its kind to receive approval for use in neoadjuvant settings in such patients in the European Union (EU).

The regulatory agency granted approval based on the Phase III CheckMate -816 clinical trial finding.

Three cycles of the combination treatment were found to offer improvement in event-free survival and pathologic complete response versus chemotherapy alone.

See Also:

The safety profile of Opdivo plus chemotherapy was noted to be in line with those observed earlier.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Opdivo-based regimens have previously received approval for usage in treating early stages of melanoma, oesophagal/gastroesophageal junction cancer and urothelial carcinoma in the region.

Bristol Myers Squibb thoracic cancers global programme lead vice-president Abderrahim Oukessou stated: “Opdivo in combination with chemotherapy is now the first and only approved immunotherapy-based neoadjuvant treatment option for non-small cell lung cancer in the EU, and we look forward to offering certain patients in Europe a solution that may help reduce their risk of disease recurrence, progression and death.”

In March 2022, the company received approval for the Opdivo combination therapy from the US Food and Drug Administration to treat adult resectable NSCLC patients.